Highlights on early-stage high-risk ER+/HER2 breast cancer: The KEYNOTE-756 study
Fatima Cardoso (Portugal) reports on the results from the KEYNOTE-756 study (LBA21).
#ESMO23: Breaking Science in Breast Cancer Video Series
Series objectives:To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews.
Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state-of-the-art management and precision oncology in Breast Cancer.
Open to all ESMO account holders. Login and watch now!
Supported by
Insights in Evolving Issues Around CDK4/6 Inhibitor Selection and Treatment Sequencing in HR+, HER2- Breast Cancer
Panel speakers: Stephen Johnston (UK) and Hope Rugo (USA), Monica Arnedos (France), moderator
Insights in Patient Selection for Immunotherapy in Breast Cancer Treatment
Panel speakers: Valentina Guarneri (Italy) and Javier Cortes (Spain); Kevin Punie (Belgium), moderator
Expert Report on Antibody Drug Conjugates for the Treatment of Advanced Breast Cancer
Philippe Aftimos (Belgium) discussed the results from the DESTINY-Breast trial (377O), the TULIP study (386MO) and the BEGONIA study (379MO).
Highlights on HER2-low unresectable and/or mBC: The DESTINY-Breast04 study
Shanu Modi (USA) reports on the results from the DESTINY-Breast04 study (376O).
Expert Report on Outcomes of CDK4/6 inhibitors in the Adjuvant Treatment of HR-positive, HER2-negative Early Breast Cancer
Matthew Goetz (USA) discussed the results from the monarchE trial (LBA17 and 240MO) and the NATALEE study (LBA23).
Highlights on the treatment of High Risk TNBC: The NeoTRIP Michelangelo study
Luca Gianni (Italy) reports on the results from the NeoTRIP Michelangelo study (LBA19).
Highlights on the Treatment of High-Risk, ER+ HER2− Primary Breast Cancer
Sherene Loi (Australia) reports on the results from (LBA20).
Highlights on the treatment of Early TNBC: The KEYNOTE-522 study
Peter Schmid (UK) reports on the results from the KEYNOTE-522 study (LBA18).
Expert Report on Patient Education/Coaching in Breast Cancer
Manfred Welslau (Germany) discussed the results from the DISCO trial (LBA22) and the IMPACT study (378O).